This week in drug discovery (21 – 25 August)

News round-up for 21-25 August by DDW Editor Reece Armstrong

A treatment for Monkeypox, spider venom for drug discovery and funding for international start-ups are some of the stories in this week’s news round-up.

Covid researchers launch Monkeypox study  

A new study investigating a potential treatment for people who have been diagnosed with monkeypox has been launched by the same team who helped develop Covid-19 treatments.

Spider venom to treat heart attacks? Australian centre examines new drug discoveries

Using deadly spider venom to treat heart attacks is one of many new discoveries currently being developed at a national research centre headquartered at The University of Queensland.

Combination treatment for AML closer to approval following EMA nod

The European Medicines Agency (EMA) has granted a Marketing Authorisation Application (MAA) for a combination treatment targeting adults with acute myeloid leukaemia (AML) who are not candidates for standard induction chemotherapy.

Bayer to advance Huntington’s Disease gene therapy trial  

A Phase I/II clinical trial targeting a treatment for Huntington’s Disease (HD) using a gene therapy has been given the clearance to go ahead in France.

International start-ups receive funding from BioInnovation 

Three international life sciences start-ups have received investment from the BioInnovation Institute (BII).

 

 

 

 

 

 

 

 

 

Suggested Reading

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free